Opiant Pharmaceuticals (NASDAQ: OPNT) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Opiant Pharmaceuticals to similar companies based off the strength of its risk, profitability, valuation, dividends, analyst recommendations, earnings and institutional ownership.
This table compares Opiant Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Opiant Pharmaceuticals Competitors||-12,670.44%||217.87%||-23.42%|
Valuation and Earnings
This table compares Opiant Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Opiant Pharmaceuticals||$14.97 million||$5.99 million||19.49|
|Opiant Pharmaceuticals Competitors||$577.88 million||$241.58 million||-6.01|
Opiant Pharmaceuticals’ competitors have higher revenue and earnings than Opiant Pharmaceuticals. Opiant Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently the more expensive than other companies in its industry.
This is a summary of current ratings and target prices for Opiant Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Opiant Pharmaceuticals Competitors||189||901||1674||66||2.57|
All “Biopharmaceuticals” companies have a potential upside of 0.31%. Given Opiant Pharmaceuticals’ competitors higher possible upside, analysts plainly believe Opiant Pharmaceuticals has less favorable growth aspects than its competitors.
Risk and Volatility
Opiant Pharmaceuticals has a beta of -0.75, meaning that its share price is 175% less volatile than the S&P 500. Comparatively, Opiant Pharmaceuticals’ competitors have a beta of 1.24, meaning that their average share price is 24% more volatile than the S&P 500.
Institutional and Insider Ownership
45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 63.8% of Opiant Pharmaceuticals shares are owned by insiders. Comparatively, 13.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.
Receive News & Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.